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Abstract
While 51 human adenoviral serotypes have been identified to date, the vast majority of adenoviral vectors designed for gene transfer have
been generated in the adenovirus serotype 5 (Ad5) backbone. Viral infections caused by Ad5 are endemic in most human populations and
the majority of humans carry preexisting humoral and/or cellular immunity to Ad5 which may severely limit the use of Ad5-based vectors
for gene therapy applications. To circumvent this preexisting Ad5 immunity, we have identified Ad35 as an alternative adenoviral serotype
to which the majority of humans do not have neutralizing antibodies. Importantly, Ad35 can be grown to high titers with a low
particle-to-PFU ratio. As a prerequisite for the development of Ad35 for use as a gene transfer vector, a genome organization map was
constructed using the available Ad35 sequence information, and E1a-deficient Ad35 vectors encoding marker genes were generated. Ad35
biodistribution in mice was assessed following intravenous administration and compared with that of Ad5. Extremely low levels of Ad35
were detected in all organs evaluated, including liver, lung, spleen, and bone marrow, while Ad5 displayed high transduction of these organs.
Due to the lack of Ad35 liver tropism, minimal hepatotoxicity was observed in mice treated with Ad35. Furthermore, the half-life of Ad35
in mouse blood was found to be two to three times longer than that of Ad5. These data suggest that either mice do not express the Ad35
cell surface receptor or that Ad35 does not efficiently transduce mouse cells in vivo following systemic delivery. Therefore, to begin to
elucidate the Ad35 cell entry mechanisms, in vitro competition studies were performed. These data demonstrated that Ad35 cell entry is
CAR independent, and may involve protein(s) expressed on most human cells.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Several attractive features of adenoviruses make them
suitable candidates for development as gene transfer vec-
tors. Some of these features include: well-studied biology,
growth to high titers, and extremely high efficiency in de-
livery of therapeutic genes to both dividing and nondividing
cells in vivo and in vitro. Although 51 human adenoviral
serotypes have been recognized to date, most of the cur-
rently used human adenoviral vectors for gene transfer are
based on the subgroup C adenoviral serotypes 2 and 5. The
primary reason for the selection of these two serotypes for
development as vectors is their well-characterized genomes
and favorable growth characteristics. However, preclinical
and clinical studies with these vectors exposed several lim-
itations associated with their use in human gene therapy.
One major limitation is the presence of preexisting immune
responses in humans. Viral infections due to subgroup C
adenoviruses are endemic in most human populations. An-
tibodies specific to adenovirus were detected in 97% of
individuals and more than 50% of people carry preexisting
humoral and cellular immune responses to Ad2 and Ad5
(Chirmule et al., 1999). Preexisting antibodies can neutral-
ize the vector and may block vector uptake and transduction
in vivo (Smith et al., 1996). Furthermore, adenoviral vector
preimmunization in mice was demonstrated to significantly
increase vector-mediated liver toxicity on reexposure
(Vlachaki et al., 2002), and the presence of anti-adenovirus
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antibodies in human blood may activate the complement
system and induce inflammatory reactions in the presence of
adenovirus (Cichon et al., 2001). Thus, preexisting immu-
nity to Ad5 may severely limit the use of these vectors for
gene therapy, especially for systemic delivery applications.
Several approaches have been employed to circumvent
this preexisting immunity. Some of the approaches included
transient immune suppression at the time of vector delivery
(Smith et al., 1996), induction of tolerance to adenoviral
capsid proteins (Yang et al., 1999; Ilan et al., 1998), plas-
mapheresis to remove adenovirus-specific antibodies (Rah-
man et al., 2001), coating of adenoviruses with polymers
(Fisher et al., 2001; Croyle et al., 2002), development of
animal adenoviruses, such as bovine and porcine, as vectors
(Reddy et al., 1999a,b), and use of chimeric vectors in
which proteins carrying neutralization epitopes are swapped
with those from rare adenoviral serotypes (Roy et al., 1998;
Miyazawa et al., 1999). Each of these approaches had lim-
ited success in rodent models, and the utility of these meth-
ods for treatment of humans remains unclear.
An alternative strategy, which is receiving increasing
attention, is the development of vectors derived from alter-
native human adenoviral serotypes which are underrepre-
sented in the human population. Indeed, administration of
an Ad2-based vector in Ad5 immunized mice resulted in
efficient transduction of mouse tissues, demonstrating the
utility of this strategy (Mastrangeli et al., 1996, Mack et al.,
1997). However, both Ad2 and Ad5 are closely related
serotypes from subgroup C. Historically, adenovirus has
been classified into six major subgroups, A–F, according to
their oncogenic and hemagglutination properties and their
DNA homology (reviewed by Shenk, 1996). Subgroup C
adenoviruses have been used predominately for the gener-
ation of gene transfer vehicles due to their favorable growth
properties, broad tropism, and well-studied genome. To
date, few gene therapy vectors have been generated from
adenoviruses from subgroups other than C (Abrahamsen et
al., 1997).
In this work, we screened 200 human serum samples for
adenovirus neutralization, and identified Ad35 as a serotype
that is underrepresented in the human population. Serotype
35 belongs to subgroup B and was first identified in 1975
from the lungs and kidneys of a renal transplant patient with
a fatal infection (Myerowitz et al., 1975). More recently,
Ad35 was isolated from urine samples or urinary tracts of
renal and bone marrow transplant recipients and immuno-
compromised AIDS patients (Flomenberg et al., 1987).
Based on the DNA homology, the members of subgroup B
are divided into two clusters, named B1 and B2 (Wadell,
1984). The B1 cluster is characterized by tropism for respi-
ratory epithelium and includes Ad3, 7, 16, and 21. The B2
cluster displays tropism for the urinary tract, and includes
serotypes Ad11, 14, 34, and 35 (Wadell, 1984). Basler and
colleagues (Basler et al., 1996; Basler and Horwitz, 1996)
reported the nucleotide sequence and transcription map for
the early region 3 (E3) of Ad35, while, more recently, the
complete nucleotide sequence of the Ad35 genome has been
determined (GenBank Accession No. X049983). However,
to date, a genome organization map of Ad35 has not been
available.
This report describes the development of Ad35 into
early-generation, E1a- and E1-deficient gene transfer vec-
tors. Ad35 biodistribution, hepatotoxicity, and blood clear-
ance rate in mice following systemic administration were
evaluated. The relative Ad35 transduction efficiency of sev-
eral human cell lines and two mouse cell lines was assessed
and compared with that of an Ad5 vector. Finally, Ad35 in
vitro growth characteristics and cell entry mechanisms were
evaluated.
Results
Human serum screening and Ad35 genome organization
Ad35 had been previously identified as a serotype that is
rare in the human population (Flomenberg et al., 1987). To
verify these data, a total of 200 human serum samples
collected from the United States, Europe, and Japan were
tested for the presence of neutralizing antibodies against
Ad5 and Ad35 (Fig. 1). As expected, the majority of human
serum samples, 109, contained neutralizing antibodies to
Ad5, indicating widespread prevalence of Ad5 exposure.
Interestingly, a very high percentage (41%) of serum sam-
ples had titers 1:8 against Ad5. In contrast, 17.5% of the
serum samples tested positive for neutralizing antibodies
against Ad35, and most of these samples displayed low
Fig. 1. Ad5 and Ad35 neutralizing antibodies in human serum. A total of
200 human serum samples collected from the United States, Europe, and
Japan were screened for the presence of Ad5 and Ad35 neutralizing
antibodies. Neutralizing antibody titers were scored as the reciprocal of the
highest dilution of serum that prevented CPE formation. Black bars rep-
resent percentages of samples with detectable antibodies to Ad5, and gray
bars represent percentages of samples with anti-Ad5 titers 8. Open bars
represent percentages of serum samples with detectable anti-Ad35 anti-
bodies, and striped bars represent percentages of serum samples with
anti-Ad35 antibody titers 8. USA, Europe, and Japan indicate samples
collected from these locations. “All” represents a compilation of antibody
titer data from all samples. The numbers above the bars indicate the
percentages of samples with a positive antibody titer.
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antibody titers. Interestingly, only 3.5% of serum samples
displayed Ad35 antibody titers 1:8. A similar trend was
displayed in the samples from all three locations (Fig. 1).
These data suggested that Ad35 was a promising serotype
for vector development.
While the complete nucleotide sequence of the Ad35
genome is available (GenBank Accession No. AX049983),
the genome organization had not been published. Therefore,
as the first step toward Ad35 vector development, we gen-
erated a genome organization map by comparison to the
genome of Ad5 and using conserved promoter sequences,
cap sites, splice donor and splice acceptor sites, and poly(A)
signal sites (Fig. 2). We performed a BLAST search of the
GenBank database using the translated amino acid se-
quences for the predicted Ad35 open reading frames of at
least 70 amino acids. While the Ad5 genome is 35,935 bp
with a G C content of 55.2%, the Ad35 genome is 34,794
bp with a G  C content of 48.9%. The genome of Ad35 is
flanked by 137-bp inverted terminal repeats (ITRs), which
are longer than those of Ad5 (103 bp). The packaging signal
of Ad35 is located at the left end of the genome with five
putative “A” repeats. The locations of all the Ad35 early
regions, E1A, E1B, E2A, E2B, E3, and E4, are similar to
those in other human adenoviruses for which the complete
nucleotide sequence is available. Similarly, the sites of the
intermediate region genes encoding pIX and IVa2 in the
genome of Ad35 are also conserved. The late transcription
unit of Ad35 is transcribed from the major late promoter
(MLP), located at 16.9 map units. The late mRNAs in Ad35
can be divided into five families of mRNAs (L1–L5), de-
pending on which poly(A) signal is used by these mRNAs.
Based on the MLP consensus initiator element, and splice
donor and splice acceptor site sequences, the length of
tripartite leader (TPL) was predicted to be 204 nucleotides.
The first leader of the TPL, which is adjacent to MLP, is 45
nucleotides in length. The second leader located within the
coding region of DNA polymerase is 72 nucleotides in
length. The third leader lies within the coding region of
precursor terminal protein (pTP) of E2B region and is 87
nucleotides in length. While Ad5 contains two virus-asso-
ciated (VA) RNA genes, only one virus-associated RNA
gene occurs in the genome of Ad35. This VA RNA gene is
located between the genes coding for the 52/55K L1 protein
and pTP.
Construction of Ad35 vectors and in vitro vector
characterization
To study the potential of Ad35-based gene transfer, rep-
lication-defective vectors lacking either E1A or the entire
E1 region were generated. Two E1A-deficient vectors,
Ad35nbg and Ad35GFP, were generated. Ad35nbg contains
the E1A promoter and E1A poly(A) signal controlling ex-
pression of the -gal coding region. Ad35GFP contains the
cytomegalovirus (CMV) immediate early promoter and
simian virus 40 (SV40) poly(A) signal controlling expres-
sion of GFP. Both vectors grew to high titers in PER.C6
cells (Fallaux et al., 1998), with viral yields of more than
4000 particles per cell. A vector lacking both E1A and E1B
regions, Ad35delE1, was generated and propagated in an
E1, E2A, and E4 complementing cell line, A70.S54 (Gor-
ziglia et al., 1999). Yields of Ad35delE1 were more than
2500 particles per cell.
To compare the gene transfer efficiency of Ad35-based
Fig. 2. Ad35 genome organization. The Ad35 genome organization map is based on sequence homologies to other adenovirus serotypes. The central solid
line represents the Ad35 genome (34,794 bp) and arrows below and above the line represent mRNA from the right (r) and left (l) strands, respectively. Solid
lines indicate the sequences present in mature mRNA, dotted lines represent introns, and arrowheads indicate poly(A) sites and direction of transcription. The
locations of early region genes (E), late region genes (L), MLP (major late promoter), TPL (tripartite leader represented by stars), and VA (virion-associated)
RNA genes are displayed. The locations of genes within the early and late regions are also identified. The locations of genes coding for hexon (hex), protease
(pro), and fiber (fib) are also displayed.
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vectors with that of Ad5 vectors, a panel of established
human and mouse cell lines were transduced with Ad35GFP
or Av1GFP. Av1GFP is an E1/E3-deficient early-generation
Ad5-based vector containing a GFP expression cassette
under the control of Rous sarcoma virus (RSV) promoter,
tripartite leader, and SV40 poly(A) signal. The transgene
delivery into these cells was monitored by FACS analysis
48 h postinfection. At the tested multiplicity of infection,
both Ad35GFP and Av1GFP were able to transduce 100%
of 293 cells and PER.C6 cells (Table 1). Higher transduc-
tion efficiencies with Ad35GFP were observed in both in
LNCaP and PC3 prostate tumor cell lines and in H460
human non-small cell lung cancer cells compared with the
Ad5-based vector. Both the Ad35 and Ad5 vectors dis-
played similar gene delivery efficiencies in A549 human
lung carcinoma cells and Hep3B liver carcinoma cells. Only
one cell line, PC3M human prostate adenocarcinoma cells,
displayed a higher transduction efficiency with the Ad5-
based vector. Interestingly, no transduction of mouse JC,
adenocarcinoma, and CMT-64 mouse lung carcinoma cells
was observed with Ad35GFP, even at a dose of 1000 par-
ticles per cell. These data demonstrate the potential utility of
Ad35-based vectors for human gene transfer.
In vivo Ad35 biodistribution, toxicity, and blood
clearance rate
The biodistribution of Ad35 in mice was evaluated fol-
lowing intravenous administration of the wild-type virus at
a dose of 1.25  1012 particles/kg, and compared with that
of wild-type Ad5. The viruses were delivered to groups of
12 female C57B1/6 mice on Day 0. Groups of animals were
sacrificed at Days 1 and 4 and selected tissues were ana-
lyzed for the presence of viral DNA by Southern analysis
(data not shown) and a sensitive hexon-based real-time PCR
assay (Table 2). Both quantitation methods displayed sim-
ilar results. While Ad5 displayed 978 copies of viral DNA
per cellular genome in the liver at Day 1, which declined to
44 viral DNA copies at Day 4, Ad35 displayed 6.5 copies of
viral DNA per cellular genome in the liver at Day 1 which
declined to less than 0.5 copy at Day 4. It is probable that
the higher DNA content in the liver for both Ad5 and Ad35
at Day 1 may be due to uptake of the virus by Kupffer cells
(Lieber et al., 1997; Worgall et al., 1997, Tao et al., 2001).
The relative hepatotoxicities of Ad5 and Ad35 were
assessed by analysis of plasma from virus-treated animals
for the presence of liver enzymes, aspartate aminotransfer-
ase (AST) (Fig. 3), alanine aminotransferase (ALT), and
alkaline phosphatase (AP, data not shown). One day after
treatment, mice that received Ad35 and Ad5 displayed 2-
and 5-fold increases in AST levels, respectively. These
levels returned to baseline by Day 4 for mice that received
Ad35. In contrast, in mice treated with Ad5 these levels
increased by 40-fold by Day 4. These data suggest that
Ad35 may be less hepatotoxic than Ad5 in mice.
The blood clearance kinetics of Ad35 and Ad5 vectors
were studied in mice following systemic delivery of vectors
expressing GFP. Mice were bled at different time intervals,
and aliquots of plasma were used to transduce cells. The
amount of virus remaining in the blood was assessed by
quantitation of GFP expression in transduced cells. The
circulating levels of virus particles immediately after vector
administration were estimated using the total number of
injected transducing units and on the assumption that 7.3%
of mouse body weight is blood (Alemany et al., 2000).
Within the first 2 min of vector administration, large, 196-
Table 1
In vitro Ad5- and Ad35-mediated transduction of human
and mouse cell linea
Cell line Ad5GFP Ad35GFP
293 100 1.2 100  1.9
A549 60 7.44 74  3.2
PER.C6 100 1.7 100  1.1
H460 25 4.2 41  2.8
Hep3B 74 4.8 66  7.5
LNCaP 42 5.2 61  1.9
PC3 6 0.2 48  1.5
PC3M 71 3.5 50  2.7
CMT-64 (mouse) 47 1.3 0.085  0.007
JC (mouse) 23.4 0.95 0.9  0.03
a Cells were transduced at 25 particles per cell. Transduced cells were
monitored for GFP expression by flow cytometry at 48 h postinfection.
Data are presented as the mean percentage of cells expressing GFP from
three experiments SD.
Table 2
Biodistribution of Ad5 and Ad35 vectors in mice as determined by hexon based real-time PCRa
Day postinjection Liver Spleen Lung Heart Kidney Marrow
Ad5
Day 1 978  134.35 0.72  0.33 0.69  0.22 0.11  0.09 0.06  0.04 0.19  0.13
Day 4 44.12  47.28 0.57  0.49 0.29  0.08 0.06  0.02 0.06  0.04 0.29  0.07
Ad35
Day 1 6.45  1.92 2.06  0.36 0.29  0.09 0.05  0.02 0.05  0.02 0.08  0.04
Day 4 0.45  0.26 0.07  0.04 0.08  0.06 0.02  0.01 0.03  0.03 0.02  0.01
a The real-time PCR was performed as described under Materials and Methods. Quantification of adenovirus copy number was performed using a standard
curve consisting of dilutions of adenovirus DNA from 1,500,000 copies to 15 copies in 10 ng of mouse genomic DNA. The average number of total copies
was normalized to copies per cell based on the amount of input DNA calculated using a genome size of 6  109 bp. Data are displayed as means SD.
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and 306-fold reductions in Ad35 and Ad5 vector titers,
respectively, were observed (Fig. 4). After this initial rapid
decline, the circulating levels of Ad5 and Ad35 reduced by
half in 4.97 and 11.95 min respectively. Therefore, 2 min
following vector administration, the circulation time of
Ad35 in mice was approximately 2.4 times longer than that
of Ad5. The clearance rates of Ad5 and Ad35 in mouse
blood were similar 30 min after vector administration. As a
control, to rule out direct inactivation of vectors by blood
components, separate aliquots of the vectors were incubated
with heparinized mouse blood for 1 h prior to separation of
plasma after which A549 cells were transduced. No signif-
icant drop in vector titers was observed (data not shown).
Taken together, the in vitro mouse cell line transduction
results, the in vivo biodistribution, and blood clearance
analyses suggest that mice do not contain the Ad35 cell
surface receptor.
Ad35 cell entry mechanism
To understand the entry pathways used by Ad35 and to
determine if Ad35 uses CAR as a primary receptor, com-
petition assays with Ad5 fiber protein were performed (Fig.
5). Ad35 entered A549 cells equally efficiently with or
without blocking of CAR. In contrast, Ad5 entry was
greatly inhibited when fiber was used to compete for CAR
binding. These data demonstrate that Ad35 transduction is
CAR-independent.
Discussion
In this work, we evaluated Ad35 as a novel serotype for
gene transfer vector development. Ad35 was chosen for
several reasons, including favorable growth characteristics
and broad in vitro tropism. Foremost, Ad35 displayed lim-
ited penetrance in the human population. Indeed, screening
Fig. 3. Ad35 hepatotoxicity in mice. Aspartate aminotransferase (AST)
levels were measured in the plasma of mice (n  6) treated with 1.25 
1012 particles/kg wt Ad5 or wt Ad35 virus. Plasma was collected on Days
1 and 4. Filled bars represent Ad5 and open bars represent Ad35. The bar
labeled “Neg” represents pretreatment AST levels (n  3). The mean
values and standard deviations are displayed.
Fig. 4. Circulation time of Ad5 and Ad35 in mouse blood. Mice in cohorts of three were treated with 3  1012 particles/kg of either Av1GFP or Ad35GFP
and bled at the indicated times. Plasma was used to transduce A549 cells, cells were harvested, and GFP expression was quantitiated by flow cytometry to
determine the transducing particles per microliter of plasma. Vector input in transducing units at T0 was calculated by dividing the total injected particles
with the total amount of blood in mice assuming 7.3% of body weight of mouse is blood (Alemany et al., 2000). F, Ad5; Œ, Ad35. Data are plotted as mean
values and standard deviations.
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of 200 human serum samples collected from around the
world revealed that the prevalence of neutralizing antibod-
ies to Ad35 was only 17% compared with more than 50%
for Ad5. These data are consistent with a previous study
(Flomenberg et al., 1987). Interestingly, the majority of
Ad5-positive serum samples had high neutralizing antibody
titers, whereas the vast majority of Ad35-positive serum
samples had low titers. These observations suggest that Ad5
infections in humans not only are widespread but may also
be recurrent or persist as latent infections. However, it is
currently unclear why the majority of humans lack neutral-
izing antibodies to Ad35, especially since in vitro analyses
revealed that Ad35 transduced the vast majority of the
human cell lines as well as or better than Ad5. Ad35 was
isolated from immunocompromised patients (Flomenberg et
al., 1987), suggesting that the virus may not replicate effec-
tively in the presence of a normal immune system.
The E3 region of subgroup C adenoviruses is thought to
function in modulation of the host immune system (Wold et
al., 1999). However, the E3 region of Ad35 differs from that
of Ad5 in several ways. For example, the promoter of the
Ad35 E3 region lacks a second NF-B binding site, sug-
gesting a difference in the mechanism by which the E3
promoter is activated following immune stimulation and in
the lymphoid tissue (Basler and Horwitz, 1996). In addition,
the E3 region of Ad35 has the potential to encode two
proteins, 20.3 and 20.6 kDa, the purposes of which are
currently unknown (Basler and Horwitz, 1996). Finally, the
Ad35 E3 region lacks the adenovirus death protein (Basler
and Horwitz, 1996), which plays a major role in the release
of Ad2 from infected cells (Tollefson et al., 1996). Taken
together, the differences in the E3 regions of Ad5 and Ad35
may influence the immune response following exposure to
these serotypes in the human population.
The availability of the complete nucleotide sequence of
Ad35 from GenBank was useful and allowed us to construct
a tentative genome organization map based on sequence
homology to other adenovirus serotypes. Such a map was
critical for the generation of several E1- and E1A-deficient
vectors. The genome organization of Ad35 is similar to that
of Ad5 with minor differences. Unlike Ad5, which has two
VA RNA genes, Ad35, similar to other serotypes in sub-
groups A, F, and B2 (Ma and Mathews, 1996), has only one
VA RNA gene, RNAI. Adenoviral VA RNAI was shown to
stimulate protein synthesis in infected cells (O’Malley et al.,
1989) and antagonize the interferon-induced host antiviral
defense system. Another striking difference between Ad5
and Ad35 is that the Ad35 fiber protein, like other subgroup
B viruses, is short, 323 amino acids (aa), and contains only
six repeats in the shaft region (Basler et al., 1996). In
contrast, the Ad5 fiber is 581 aa and contains 22 repeats in
the shaft (Chroboczek et al., 1995). Interestingly, the Ad35
fiber knob, similar to other subgroup B viruses (Roelvink et
al., 1998; Shayakhmetov et al., 2000), does not contain the
coxsackie B virus and adenovirus receptor (CAR) binding
motif. Many viruses, such as those belonging to subgroups
A, C, and E, do contain this motif (Bergelson et al., 1998;
Roelvink et al., 1998). These observations suggest that
Ad35 does not use the CAR cell surface receptor for cell
entry. Indeed, we found that purified Ad5 fiber protein did
not inhibit Ad35 cell transduction. The Ad35 penton base,
like that of Ad5, contains the arginine–glycine–aspartic
acid (RGD) motif that has been implicated in integrin bind-
ing (Wicham et al., 1993; Li et al., 2002), suggesting that,
similar to Ad5, Ad35 may use integrins for internalization.
Identification of the specific Ad35 cell surface receptor is
currently under investigation.
In vitro transduction studies revealed that Ad35 trans-
duced the majority of human cell lines tested as well as or
better than Ad5, suggesting that the specific receptor for
Ad35 is abundantly expressed on human cells and may be
ubiquitous. In contrast to the in vitro human cell line trans-
duction data, transduction of two mouse cell lines was
extremely inefficient. Likewise, investigation of the biodis-
tribution of Ad35 following systemic administration in mice
revealed that all mouse tissues analyzed, including liver,
lung, heart, kidney, and bone marrow, showed extremely
low transduction. Not surprisingly, Ad35 displayed low
hepatotoxicity, most likely due to the low transduction ef-
ficiency of mouse liver. Finally, the circulation time of
Ad35 in mouse blood was two- to threefold longer than that
of Ad5. Taken together, these data demonstrate that Ad35
does not efficiently transduce mouse cells in vitro or in vivo
and suggest that rodents may lack the Ad35 cell surface
receptor.
In the present study, it was demonstrated that Ad35
vectors lacking only the E1A region could be generated and
propagated in PER.C6 cells, cells that constitutively express
the E1 proteins of Ad5. These data suggest that E1A pro-
teins of Ad5 can complement those of Ad35. Similarly, it
was demonstrated previously that the E1A proteins of Ad5
could complement human adenovirus serotypes belonging
to both subgroups C and B (Abrahamsen et al., 1997), as
well as bovine and porcine adenoviruses (Reddy et al.,
1999a,b). In contrast, the Ad35 vector lacking both the E1A
Fig. 5. Cell transduction competition analyses. A549 cells were transduced
with 200 particles per cell of Ad5 or Ad35, in the absence (None) or
presence of Ad5 fiber protein (Fiber) or mock-transduced (Mock). Trans-
duction was quantitated as the percentage of cells that were hexon positive
following incubation with a FITC-conjugated hexon antibody and analysis
by flow cytometry. Data are plotted as mean values and standard devia-
tions.
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and E1B coding regions could not be generated and grown
in PER.C6 cells, suggesting that the E1B proteins of Ad5
could not complement Ad35. This limitation was overcome
by using a complementing cell line that expressed both the
E4 proteins and the E1 proteins of Ad5. Such a cell line,
A70.S54 was developed previously for use in the generation
of Ad5-based vectors lacking the E1, E2A, and E4 regions
(Gorziglia et al., 1999). Ornelles and Shenk (1991) reported
that the Ad5 E1B 55-kDa protein forms a complex with the
Ad5 E4 ORF6 protein, which, in turn, binds a component of
the host nucleocytoplasmic transport system to promote
selective transport of late viral mRNA. We hypothesized
that the use of E1B and E4 proteins originating from the
same serotype was required for E1B 55-kDa and E4 ORF6
association. Indeed the lack of complementation of the
E1A- and E1B-deficient Ad35 vector in PER.C6 cells and
the efficient propagation of this vector in A70.S54 cells
suggest that the Ad5 E1B 55-kDa protein and the Ad35 E4
ORF6 protein are not capable of complex formation, result-
ing in impaired transport of late viral mRNA.
The data presented in this report, including limited im-
munity to Ad35 in the human population, favorable growth
characteristics, highly efficient transduction of human cells,
and the development of replication-defective vectors, dem-
onstrate the great potential of Ad35 for human gene therapy
applications.
Materials and methods
Viruses and cells
The Holden strain of human adenovirus type 35 (Ad35)
purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) was cultivated in PER.C6 cells (Fal-
laux et al., 1998). The cells were grown in Dulbecco’s
modified Eagle medium (DMEM, Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (Bio-
Whittaker, Walkersville, MD, USA) and 10 mM magne-
sium chloride (Sigma, St. Louis, MO, USA). Virus was
purified by two rounds of CsCl gradients: a one-step gradi-
ent followed by one continuous gradient centrifugation. The
purified virus concentration was determined spectrophoto-
metrically, assuming 1A260  1.1  1012 particles (Mitte-
reder et al., 1996). Viral genome integrity was confirmed by
restriction enzyme analysis of DNA isolated from CsCl-
purified vectors. Titers of purified viruses were also deter-
mined by a standard plaque assay using PER.C6 cells. The
yields of wild-type (wt) Ad35 from PER.C6 cells were
greater than 20,000 particles per cell, with particle to PFU
ratios less than 15. An E1, E2A, and E4 complementing cell
line, A70.S54 (Gorziglia et al., 1999), was used for gener-
ation and cultivation of the E1 deletion mutant of Ad35. The
cells were grown in improved minimum essential medium
(IMEM, Biosource International, Rockville, MD, USA)
supplemented with 5% fetal bovine serum and 1 g/ml
tetracycline. For virus production, these cells were induced
by addition of dexamethasone and removal of tetracycline
from the medium.
Human serum samples and neutralizing antibody assays
Two hundred randomly collected human sera samples
were used in neutralization assays. These samples were
purchased from Bioheme (Salt Lake, UT, USA). Of these,
100 came from donors in the United States, 50 from Europe,
and 50 from Japan. To inactivate complement, all serum
samples were heated to 56°C for 30 min. To perform the
neutralizing antibody assay, the day before the experiment,
PER.C6 cells were seeded at a density of 3  104 cells per
well in a 96-well tissue culture plate. On the day of the
experiment, each serum sample was serially diluted (from
1:2 to 1:256) in infection medium (2% FBS in DMEM, 10
mM MgCl2). The serial dilution of each serum sample (50
l) was added to an equal volume of virus (100 TCID50). As
a control, FBS was also serially diluted and combined with
100 TCID50 of adenovirus. The virus/serum dilutions were
incubated for 1 h at 37°C. Medium was removed from the
PER.C6 cells and replaced with the virus/serum mixtures
and incubated for 1 h at 37°C. Control wells were infected
with equal amounts of virus (100 TCID50) without addition
of serum. The infection mixture was then removed and
replaced with growth medium and incubated for 10 days
until CPE occurred in the control wells. The neutralizing
antibody titer was scored as the reciprocal of the highest
serum dilution that could prevent CPE formation in PER.C6
cells.
Construction of E1a-deficient Ad35 vectors
First, an Ad35 full-length clone was constructed. The left
(985 bp) and right (5403 bp) terminal fragments generated
by digestion of Ad35 genomic DNA with PstI were cloned
separately into pGEM-3S. Plasmid pGEM-3S was derived
from pGEM-3Z (Promega, Madison, WI, USA), by intro-
duction of a I-SceI recognition sequence into the polylinker.
The nucleotide numbers of the Ad35 genome referred to in
this report are according to GenBank Accession No.
AX049983. The cloned terminal fragments with upstream
I-SceI sites were then inserted into pBlueScript (Stratagene,
La Jolla, CA, USA) to generate pBSAd35L&RTF. The
plasmid pFLAd35, which contains the full-length Ad35
genome bordered by I-SceI sites, was generated by combin-
ing the PstI-linearized pBSAd35L&RTF and the genomic
DNA of wild-type Ad35.
The vector Ad35GFP, which contains a GFP expression
cassette replacing the E1a region of Ad35, was generated in
several steps. First the plasmid pFLAD35, containing the entire
Ad35 genome in pBlueScript, was digested with SphI, and
the fragment containing the left and right terminal fragments
(nucleotides (nt) 1–3094 and 32,683–34,794, respectively)
of Ad35 was gel purified and self-ligated to generate
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pAd35L&RSph. By using polymerase chain reaction (PCR),
1115 bp corresponding to the promoter and coding sequences
of E1A between bp 338 and 1454 were deleted and a recog-
nition sequence for PmeI was inserted into pAd35L&RSph to
generate pAd35L&RsphdelE1A. The gene coding for GFP
under the control of CMV immediate early promoter and
SV40 poly(A) signal obtained from pEGFP (Clontech,
Palo Alto, CA, USA) was cloned into the PmeI site of
pAd35L&RSphdelE1A to generate pAd35L&RsphdelE1AGFP.
The plasmids pFLAd35delE1A and pFLAd35delE1AEGFP,
which contain the full-length Ad35 DNA with the E1A deletion
and GFP coding region replacing the E1A coding region, respec-
tively, were generated by combining SphI-linearized
pAd35L&RsphdelE1A and pAD35L&RSphGFP and the
genomic DNA of wild-type Ad35, respectively. To generate the
viruses Ad35v0.5 and Ad35GFP, pFLAD35delE1A and
pFLAd35delE1AGFP respectively were digested with I-SceI and
transfected into PER.C6 cells. The E1 deletion mutant of Ad35
was also generated in several steps. First the plasmid
pFLAd35delE1A was digested with NruI, and the fragment con-
taining the left and the right terminal fragments of Ad35 was gel
purified and self-ligated to generate pAd35L&RNrudelE1A. By
using PmeI and PacI restriction enzyme digestions, a 2579-bp
fragment (between bp 338 and 2917) spanning the E1A poly(A)
signal, complete open reading frame (ORF) of E1B 19 kDa, and
first 1001 bp of the ORF of E1B 55 kDa was deleted from
pAd35L&RNrudelE1 to generate pAd35L&RNrudelE1. The
plasmid pFLAd35delE1, which contains the full-length Ad35
DNA with the E1 deletion, was generated by combining NruI-
linearized pAd35L&RNrudelE1 and the genomic DNA of wild-
type Ad35. To generate the virus Ad35delE1, pFLAd35delE1
was digested with I-SceI and transfected into A70.S54 cells (Gor-
ziglia et al., 1999). A70.S54 is a stable cell line derived from
AE1-2a cells (Gorziglia et al., 1996) and expresses E1, E2a, and
E4 proteins of Ad5. The transfection of I-SceI-linearized
pFLAd35delE1 into PER.C6 cells did not result in virus genera-
tion.
The vector Ad35nbg, which contains a -galactosidase ex-
pression cassette under the control of E1A promoter and
poly(A) signal, was generated in several steps. First, the plas-
mid pAd35L&RSphnbg was generated following deletion of
E1A coding region (892 bp; from nt 559 to 1451) from
pAd35L&RSph and insertion of a DNA fragment encoding
-galactosidase. Next, the plasmid, pFLAd35delE1Anbg was
generated by combining the wild-type Ad35 genomic DNA
and SphI-linearized pAd35L&RSphnbg. The vector Ad35nbg
was generated in PER.C6 cells following transfection of I-
SceI-linearized pFLAd35delE1Anbg.
Animals and study design
Female C57B1/6 mice, 4–6 weeks old, purchased from
Harlan Sprague Dawley (Indianapolis, IN, USA), were used
in the study. For the biodistribution study, doses of 1.25 
1012 particles/kg wt Ad5 and wt Ad35 viruses were deliv-
ered intravenously using the lateral tail vein in a dose
volume of 10 ml/kg on Study Day 0. Blood was collected
into sodium citrate solution by orbital sinus bleeds on Days
1, 1, and 4 of virus administration. At the time of nec-
ropsy, liver, spleen, kidney, lungs, heart, and bone marrow
(femur) were collected and used for genomic DNA extrac-
tion. The plasma levels of aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and alkaline phos-
phatase (AP) were measured by AniLytics, Inc. (Gaithers-
burg, MD, USA). To compare the blood circulation time of
Ad5 to Ad35 in mice, mice (n  3) were treated with 3 
1012 particles/kg of either Av1GFP or Ad35GFP and bled at
2, 5, 10, 15, 20, 30, and 60 min postinjection. The animals
were sacrificed following the 60-min bleed. Plasma was
separated from the blood immediately after collection, di-
luted in infection medium, and used to transduce A549
cells. The cells were harvested and fixed 24 h postinfection
and FACS analysis was performed to detect the fraction of
GFP-positive cells. All animal procedures were performed
at Genetic Therapy, Inc., in an AAALAC-accredited animal
facility in accordance with the Animal Welfare Act and
institutional guidelines for the humane treatment of labora-
tory animals.
Organ DNA analyses
Genomic DNA was isolated from collected organs using
the Qiagen Blood and Cell Culture DNA midi kit (Qiagen
Inc., Valencia, CA, USA) according to manufacturer’s in-
structions. To determine the Ad5 DNA content in each
tissue, a real-time PCR assay was used as described by
Smith et al. (2002). Ad35 viral DNA content in DNA
collected from mouse organs was determined by Ad35
Hexon Taqman real-time PCR assay. PCR primers and a
Taqman probe specific to Ad35 hexon sequences were de-
signed using Primer Express software Version 1.0 (Applied
Biosystems, Foster City, CA, USA). Primer and probe se-
q u e n c e s w e r e : ( h e x o n f o r w a r d ) p r i m e r 5  -
TACATGCACATCGCCGGA-3, (hexon reverse primer)
3-CGGGCGAACTGCACCA-3, and (hexon probe) 5-
FAM-ATGCTTCGGAGTACCTGAGTCCGGG-TAMRA-
3. Amplification was performed in a reaction volume of 50
l under the following conditions: 10 ng of sample DNA,
1X Taqman Universal PCR Master Mix (Applied Biosys-
tems), 900 nM forward primer, 300 nM reverse primer, and
100 nM hexon probe. Thermal cycling conditions were:
2-min incubation at 50°C, 10 min at 95°C, followed by 40
cycles of successive incubation at 95°C for 15 s and 60°C
for 1 min. Data were collected and analyzed using the 7700
Sequence Detection System software version 1.6.3 (Applied
Biosystems). Quantification of adenovirus copy number
was performed using a standard curve consisting of dilu-
tions of adenovirus DNA from 1,500,000 copies to 15
copies in 10 ng of mouse DNA. The average number of total
copies was normalized to copies per cell based on the input
DNA weight amount and a genome size of 6  109 bp.
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In vitro cell transduction and competition analyses
To determine and compare the transduction efficiency of
Ad35GFP with that Av1GFP, selected human cell lines
were transduced with these two vectors at 25 particles per
cell (PPC) for 2 h at 37°C in a total volume of 0.5 ml of
culture medium containing 2% heat-inactivated fetal bovine
serum (FBS) in six-well plates. The infection medium was
replaced with 2 ml of the appropriate culture medium con-
taining 4% FBS. The cells were incubated for 48 h to allow
for GFP expression. The cell monolayer was then detached
by trypsin treatment, washed, and fixed. The percentage of
transduction was determined by flow cytometry. Each vec-
tor transduction was carried out in triplicate and the average
percentage of transduction determined. Human embryonic
kidney cells, 293, were cultured in DMEM containing 10%
FBS. Human non-small cell lung carcinoma (H460) and
human prostate cancer (PC3M-2AC6) cells were cultured in
RPMI-1640 medium containing 10% FBS. Human hepato-
cellular carcinoma (Hep3B) cells, were cultivated in mini-
mal essential medium containing 10% FBS. Human prostate
cancer (LNCaP) cells were cultured in RPMI containing
10% FBS, L-glutamine (2 mM), nonessential amino acids
(0.1 mM), sodium carbonate (0.075%), and sodium pyru-
vate (1 mM). Human prostate (PC3) cancer cells were
cultured in RPMI supplemented with 10% FBS and L-
glutamine (2 mM). CMT-64 is a murine small cell lung
carcinoma and was maintained in DMEM containing 10%
FBS. Murine mammary adenocarcinoma (JC) cells were
cultured in RPMI containing 10% FBS.
For the competition analyses, the day before the exper-
iment, A549 cells were seeded at a density of 4  105 cells
per well in a 12-well tissue culture dish in the growth
medium (Richter’s medium containing 10% FBS). To de-
termine the role of CAR in virus entry, duplicate wells of
cells were incubated with infection medium (Richter’s me-
dium plus 2% FBS) containing purified Ad5 soluble fiber
protein (20 ug/well) at room temperature for 15 min. Virus
particles corresponding to 200 ppc for Ad5 and Ad35 were
then added to the cells and the plates were further incubated
at 37°C for 1 h, after which 1 ml of fresh growth medium
was added, and plates were further incubated at 37°C for
24 h. The following day, cells were fixed with paraformal-
dehyde, permeabilized by treating with Tween 20, stained
with anti-hexon mouse monoclonal antibodies conjugated to
FITC (MAB8052, Chemicon International Temecula, CA,
USA), and analyzed by flow cytometry.
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